Drug Profile
Alteminostat - Chong Kun Dang Pharmaceutical
Alternative Names: CKD-581Latest Information Update: 29 Aug 2022
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Amides; Antineoplastics; Hydroxamic acids; Indazoles; Piperazines; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
- No development reported Lymphoma
Most Recent Events
- 29 Aug 2022 Alteminostat is still in phase I trial for Multiple myeloma in South Korea (Combination therapy, Second-line therapy or greater) in South Korea (Parenteral, Injection) (Chong Kun Dang Pharmaceutical pipeline, August 2022)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in South Korea (Parenteral, Injection)
- 06 Apr 2020 Alteminostat is still in phase-I trials for Multiple myeloma in South Korea (Chong Kun Dang Pharmaceutical pipeline, April 2020)